Minimum detectable effect size for main outcomes (accounting for sample
design and clustering)
We utilize the data from similarly parameterized treatments in Drichoutis et al. (2025) to estimate the inputs to our power calculations. With an induced value of $3.00, the average offer shifted from $2.701 with a support set upper bound of $4.00 to $3.158 with a support set upper bound of $6.00. Each subject participated in both treatments. The pooled standard deviation of the two offer distributions was 0.895. In our power analysis presented below, we conservatively assume a between-treatment correlation of 0.3, compared to the actual observed correlation of 0.501.
We employ the asymptotic relative efficiency (ARE) method in our power calculation which estimates the sample size required under a parametric t-test at a given power level and converts the result to the sample size required by the nonparametric Wilcoxon signed-rank test that we use to test our primary hypothesis (Faul et al., 2009).
The sample size required under a t-test is then 51. The ARE of the Wilcoxon test is approximately 0.955, implying a sample size of 53 (Faul et al., 2009). Utilizing the actual observed correlation value of 0.509 yields a sample size of 39. In order to ensure our tests analyzing the subpopulation of risk-tolerant subjects are adequately powered, we reviewed three BRET studies reporting the proportions of risk-averse, risk-tolerant, and risk-neutral responses and found that, on average, 24.3% of participants exhibited risk-tolerant behavior (Crosetto & Filippin, 2013; Gioia, 2017; Soetevent and Romensen, 2017). Our analysis, therefore, indicates a total sample size of 218 individuals provides adequate power to test our secondary hypotheses regarding heterogeneity by risk preferences. To account for attrition and unusable responses, we plan to target 300 total respondents which would yield approximately 199 risk-averse subjects, 73 risk-tolerant subjects, and 29 risk-neutral subjects. In the event that our initial sample does not reach the required threshold of 53 risk-tolerant subjects, we intend to extend our data collection to additional subjects until the quota is met. Please see the Analysis Plan for more detail and supporting calculations.